Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson's Disease: early-phase trial registry
42 of 161 indexed Parkinson's Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #67 of 28,707 conditions by registered trial count.
161 US clinical trials · 42 currently recruiting · #67 of 28,707 conditions by registered trial count
Parkinson's Disease: 161 US clinical trials tracked, 42 recruiting.
Parkinson's Disease is the subject of 161 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 55 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 16 of these trials.
Enrollment posture brief
Registry condition parkinsons-disease
OPEN 42 | RECR 26% | LATE 21 | EARLY 55 | RANK #67 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Barrett's Esophagus (26% recruiting · 23 trials)
Parkinson's Disease lists 42 open slots (26% of 161 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson's Disease is recruiting below its size-band peers.
42 of 161 indexed trials (26.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Parkinson's Disease trials is spread across many organizations.
VA Office of Research and Development accounts for 16 of 161 trials (9.9%). 99 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinson's Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 159 trials that report a genuine target (sentinel values excluded). 100 of those (62.9%) plan for fewer than 100 participants.
-
Parkinson's Disease research is mostly interventional.
114 interventional and 47 observational studies make up this index (70.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
161 total, page 3 of 4
Ketamine for the Treatment of Depression in Parkinson's Disease
Yale University
NCT04944017
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
AstraZeneca
NCT01603069
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enterin
NCT03047629
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
Otsuka Pharmaceutical Development & Commercialization
NCT00095810
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00006077
The Effect of Rasagiline on Cognition in Parkinson's Disease
Brown University
NCT01382342
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
Baylor College of Medicine
NCT00640159
Non-invasive Neurostimulation in Parkinson's Disease
Spaulding Rehabilitation Hospital
NCT01615718
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
VA Office of Research and Development
NCT03462680
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The Cleveland Clinic
NCT02538029
Masked Faces in Parkinson Disease: Mechanism and Treatment
University of Florida
NCT00350402
Telephone-linked Home-based Exercise Training in PD
VA Office of Research and Development
NCT02898740
Psychiatric and Cognitive Manifestations of Parkinson's Disease
NYU Langone Health
NCT00360633
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
Acorda Therapeutics
NCT02807675
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
Georgetown University
NCT01497652
Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
VA Office of Research and Development
NCT01563913
Relative Bioavailability and Food Effect Study of CVN424
Cerevance Beta
NCT05635461
A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease
Virginia Commonwealth University
NCT01646333
Poised for Parkinson's - an Intervention to Increase Embodied Agency in People With Parkinson's Disease and Their Carers
University of Idaho
NCT04726709
Non-contact Boxing Training and Traditional Therapeutic Exercise for Persons With Parkinson's Disease
University of Indianapolis
NCT01014663
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Avid Radiopharmaceuticals
NCT00857532
Dance Exercise as Novel Complementary Therapy for Parkinson's Disease
Beth Israel Deaconess Medical Center
NCT01163344
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
University of Florida
NCT01168596
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Avid Radiopharmaceuticals
NCT01503944
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
NYU Langone Health
NCT00070941
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
Impax Laboratories
NCT00869791
Trichloroethylene (TCE) Exposure in an Industrial Population
University of Kentucky
NCT00839514
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
University of Nevada, Las Vegas
NCT02230267
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
Daiichi Sankyo
NCT00623363
Motor Skill Learning in People With Parkinson's Disease
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00396942
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
University of Cincinnati
NCT00526630
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
Novartis
NCT01092065
POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease
The Parkinson Study Group
NCT00234676
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
University of Miami
NCT01491022
Automated Telehealth Diagnostics for Remote Parkinson Monitoring
Great Lakes NeuroTechnologies
NCT02152319
The Motor Network in Essential Tremor: Mechanisms of Therapy
University of Florida
NCT02712515
Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
Johns Hopkins University
NCT00294554
Deep Brain Stimulation in Patients With Parkinson's Disease
Mayo Clinic
NCT00586079
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Parkinson's Disease Research, Education, and Clinical Center, Philadelphia
NCT00841464
Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease
University of California, San Diego
NCT01306539
The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients
University of Alabama at Birmingham
NCT01769690
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study
MedtronicNeuro
NCT01750242
Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
VA Office of Research and Development
NCT03607695
Motion Immune Magnetic Resonance Imaging (MRI)
Duke University
NCT02302521
Using Parkinson's Disease to Study the Role of the Substantia Nigra Pars Reticulata
University of Colorado, Denver
NCT02216435
Feasibility and Acceptability of a Physical Activity Behavior Change Intervention for Parkinson's Disease
Teachers College, Columbia University
NCT03696589
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
Oregon Health and Science University
NCT00666653
Video Based Mindfulness Based Stress Reduction
Oregon Health and Science University
NCT02705586
Study of Magnetic Fields for Treatment of Parkinson's Disease
pico-tesla Magnetic Therapies
NCT00779155
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
Impax Laboratories
NCT00253084
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 31 |
| Phase 3 | 11 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson's Disease page
161 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 42 Parkinson's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- VA Office of Research and Development sponsors the most Parkinson's Disease trials on record, review their full trial history before evaluating a specific study. See VA Office of Research and Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson's Disease condition card totals 161 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.